Pharmaceutical Chemistry with Foundation
University of ReadingPharmaceutical Chemistry with Foundation BSc (Hons) is an undergraduate degree at University of Reading, based in Reading, taught full-time over 5 years. Graduates earn £28,000 on average 15 months after finishing. Typical A-level entry is CCD - BBB.
A-Level Entry
CCD - BBB
Typical offer · UCAS
Avg. Graduate Salary
£28,000
15 months after graduation · HESA via Discover Uni
About this course
Our BSc Pharmaceutical Chemistry with Foundation course offers a broad education in chemistry, and provides you with the skills to succeed in the pharmaceutical industry. This four-year degree includes a year of foundational study before leading directly into the three-year course.
Our new pharmaceutical chemistry degree has been developed with our industrial partners to produce high quality graduates for the pharmaceutical sector – an area that already employs 67,000 people in the UK, and contributes £30.4bn to the national economy per year.
You will develop a strong grounding in basic chemistry and biology, and also cover advanced topics relevant to modern pharmaceutical chemistry. We go beyond organic chemistry – which is traditionally associated with pharmaceutical programmes – to cover many other areas of chemistry and biology. As such, we consciously address the needs of this modern and growing industry.
For more information, please visit our course page: https://www.reading.ac.uk/ready-to-study/study/subject-area/chemistry-ug/bsc-pharmaceutical-chemistry-with-foundation
Entry Requirements
Career Prospects
Graduates from this course typically go into the following occupations. Click through for salaries, employment rates and other UK degrees that lead there:
Related Courses
Course Details
- Qualification
- Bachelor of Science (with Honours) - BSc (Hons)
- Study Mode
- Full-time
- Duration
- 5 Years
- Start Date
- 2025
- Academic Year
- 2025
- Campus / Location
- Reading
- Scheme
- Undergraduate
- Subjects
- Chemistry
- Avg. Graduate Salary
- £28,000
2025-entry data — 2026 offers may differ